CVI Holdings’s Spyre Therapeutics SYRE Stock Holding History

CVI Holdings’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,862	Closed	-$2.19M	–	74
2019 Q1	$2.19M	Buy	+10,862	New	+$2.26M	2.07%	9

Other funds holding SYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CVI Holdings's SYRE Position: Q2 2019 in Review

CVI Holdings sold out of Spyre Therapeutics (SYRE) in Q2 2019, closing a stake of 10,862 shares — an estimated $2.19M sold.

CVI Holdings first reported a position in SYRE in Q1 2019 and held it in 1 quarter. The position peaked at $2.19M in Q1 2019. 77 funds tracked by Wall St. Rank hold SYRE as of Q2 2019.

CVI Holdings reported no remaining Spyre Therapeutics position as of Q2 2019 after selling out during the quarter.
CVI Holdings sold 10,862 Spyre Therapeutics shares in Q2 2019, an estimated $2.19M.
CVI Holdings first reported a position in Spyre Therapeutics in Q1 2019 and held it in 1 quarter.
CVI Holdings's Spyre Therapeutics position peaked at $2.19M in Q1 2019.
77 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2019.

Based on CVI Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.